Abstract:Targeted drug delivery using biological ligands can improve the precision of cancer therapy. However, this active targeting strategy is limited in tumor targeting and penetration abilities due to the paucity and heterogeneous distribution of targeted receptors in tumor cells, thus compromising the treatment outcomes. In this study, we developed an alternative active targeting strategy for enhanced tumor targeting and penetration through synthetic nanoparticle-mediated metabolic tumor ligand labeling for intercellular delivery of bioorthogonal chemical receptors combined with in vivo bioorthogonal click chemistry. Briefly, artificial azide-containing ligands were first labeled on perivascular tumor cells by nanoscale metabolic precursors (Az-NPs) via the enhanced permeability and retention (EPR) effect and metabolic engineering of the tumor cells. Through transport by extracellular vesicles (EVs) secreted by perivascular tumor cells, the azide-containing ligands can be autonomously transported intercellularly to adjacent cells and further spread throughout tumor tissues and label bioorthogonal ligands on cells that are not in proximity to blood vessels. Then, water-soluble dibenzocyclooctyne-modified chlorin e6 (DBCO-Ce6) was intravenously injected to react selectively, efficiently and irreversibly with the azide groups on the cell surface through an in vivo bioorthogonal click reaction. Enhanced tumor accumulation and penetration of DBCO-Ce6 was achieved through this strategy, resulting in improved therapeutic efficiency with laser irradiation for photodynamic therapy. Therefore, the artificial azide-containing ligand targeting strategy by nanoparticle-mediated metabolic labeling through the EPR effect combined with bioorthogonal click chemistry may provide an alternative strategy for enhanced tumor targeting and penetration with broad applications.

Building bioorthogonal click-release capable artificial receptors on cancer cell surface for imaging, drug targeting and delivery

Chemical Remodeling Cell Surface Glycans for Immunotargeting of Tumor Cells

Intercellular delivery of bioorthogonal chemical receptors for enhanced tumor targeting and penetration

An All-in-One Bioorthogonal System for Precise Cancer Therapy

Bioorthogonal Reaction-Mediated Tumor-Selective Delivery of CRISPR/Cas9 System for Dual-Targeted Cancer Immunotherapy.

Acid-Responsive Polymer Micelles for Targeted Delivery and Bioorthogonal Activation of Prodrug through Ru Catalyst in Tumor Cells

Enzymatic Non-Covalent Synthesis of a Versatile Platform for Bioorthogonal Prodrugs Activation to Combat Drug Resistance

Nitric Oxide-Activated Bioorthogonal Codelivery Nanoassembly for in Situ Synthesis of Photothermal Agent for Precise and Safe Anticancer Treatment

Enzymatic non-covalent synthesis of supramolecular assemblies as a general platform for bioorthogonal prodrugs activation to combat drug resistance

Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy

A High‐Efficiency Bioorthogonal Tumor‐Membrane Reactor for In Situ Selective and Sustained Prodrug Activation

Nitric Oxide‐Activated Bioorthogonal Co‐delivery Nanoassembly for In Situ Synthesis of Photothermal Agent for Precise and Safe Anti‐cancer Treatment

Tumor Cell‐Specific Metabolic Labelling of Surface Sialoglycans and Post‐Click with Multivalent Rhamnose Enable Precise Immune Killing by Endogenous Antibody

Bioorthogonal in situ assembly of nanomedicines as drug depots for extracellular drug delivery

In vivo cancer targeting via glycopolyester nanoparticle mediated metabolic cell labeling followed by click reaction.

Nanovoid-confinement and click-activated nanoreactor for synchronous delivery of prodrug pairs and precise photodynamic therapy

In Vivo Targeting of Metabolically Labeled Cancers with Ultra-Small Silica Nanoconjugates

Bacteria-Mediated Intracellular Click Reaction for Drug Enrichment and Selective Apoptosis of Drug-Resistant Tumor Cells

In-situ activation of biomimetic single-site bioorthogonal nanozyme for tumor-specific combination therapy

Chemo-Click: Receptor-Controlled and Bioorthogonal Chemokine Ligation for Real-time Imaging of Drug-Resistant Leukemic B Cells

Tunable Multivalent Aptamer-Based DNA Nanostructures to Regulate Multiheteroreceptor-Mediated Tumor Recognition.